4.38
0.01 (0.34%)
| Penutupan Terdahulu | 4.36 |
| Buka | 4.29 |
| Jumlah Dagangan | 355,022 |
| Purata Dagangan (3B) | 1,188,906 |
| Modal Pasaran | 607,757,504 |
| Harga / Jualan (P/S) | 52.58 |
| Harga / Buku (P/B) | 0.810 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Operasi (TTM) | -4,568.83% |
| EPS Cair (TTM) | -4.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -94.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.21% |
| Nisbah Semasa (MRQ) | 6.79 |
| Aliran Tunai Operasi (OCF TTM) | -415.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -310.09 M |
| Pulangan Atas Aset (ROA TTM) | -23.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Vir Biotechnology, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.30 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.57% |
| % Dimiliki oleh Institusi | 79.54% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (B of A Securities, 220.00%) | Beli |
| Median | 12.00 (174.29%) | |
| Rendah | 12.00 (Evercore ISI Group, 174.29%) | Beli |
| 12.00 (Raymond James, 174.29%) | Beli | |
| Purata | 12.67 (189.60%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 5.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Evercore ISI Group | 03 Sep 2025 | 12.00 (174.29%) | Beli | 5.51 |
| B of A Securities | 27 Aug 2025 | 14.00 (220.00%) | Beli | 5.23 |
| Raymond James | 11 Jul 2025 | 12.00 (174.29%) | Beli | 5.65 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SATO VICKI L | - | 5.00 | -22,000 | -110,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -22,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -110,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.00 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SATO VICKI L | Pengarah | 02 Sep 2025 | Jual automatik (-) | 22,000 | 5.00 | 110,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |